Quinolines as chemotherapeutic agents for leishmaniasis.

Abstract

The development of leishmanicidal quinolines and their in vitro (promastigote and amastigote) and, where applicable, in vivo activities are reviewed. This survey provides a direct comparison of bioactivity across different species(e.g. L. donovani, L. amazonensis, L. chagasi, L infantum), and in different animal models (e.g. L. donovani Balb/c mice and L. donovani infected hamsters). The progress of selected quinolines through pre-clinical development and phase I/II trials, and the lead quinoline drugs sitamaquinine and Imiquimod, are discussed in conjunction with delivery systems and combination therapies.

• Authors: Kristie A Reynolds, Wendy A Loughlin, David J Young
• Journal: Mini reviews in medicinal chemistry (Mini Rev Med Chem) Vol. 13 Issue 5 Pg. 730-43 (Apr 01 2013) ISSN: 1875-5607 [Electronic] Netherlands
• PMID: 23469781 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Aminoquinolines
• Antiprotozoal Agents
• Quinolines
• Primaquine
• Imiquimod
• 8-aminoquinoline

Topics

• Aminoquinolines (chemistry, pharmacology, therapeutic use)
• Animals
• Antiprotozoal Agents (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Humans
• Imiquimod
• Leishmania (drug effects)
• Leishmaniasis (drug therapy)
• Primaquine (chemistry, pharmacology, therapeutic use)
• Quinolines (chemistry, pharmacology, therapeutic use)
• Structure-Activity Relationship